Corona vaccine update: Glenmark Provide fevipiravir for 103 per tablet
Mumbai-based Glenmark Pharmaceuticals have launched a replacement antiviral - Favipiravir with name FabiFlu - for the treatment of mild to moderate Covid-19 patients. The firm has become the primary Indian company to commercially launch the antiviral . Indian drug regulator Drug Controller General of India (DCGI) gave the corporate approval for marketing and manufacturing after which the merchandise was launched within the Indian market today. A pack of 34 tablets of FabiFlu has been priced at Rs 3,500 (Rs 103 per tablet). The dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets each day for 14 days of the treatment. However, it should only be taken after a doctor's prescription. A clinical test was conducted by Glenmark among 90 mild and 60 moderate Covid-19 patients across 11 sites in India. The drug is claimed to possess an efficacy of over 80% within the treatment of mild to moderate Covid-19 patients. Delhi-based Brinton Pharmaceuticals, Bengaluru-based Strides Pharm